Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Transcript

Why It Matters

The regulatory win and capacity boost give Amphastar a competitive edge in high‑margin generics, while the modest revenue decline and margin outlook signal both growth opportunities and cost challenges for investors.

Key Takeaways

• Net revenue $719.9M, down 2% YoY.
• Baqsimi sales up 12% to $185.4M.
• FDA approved ipratropium bromide HFA, 180‑day exclusivity.
• Rancho Cucamonga expansion will quadruple production capacity.
• 2026 revenue forecast mid‑ to high‑single‑digit growth.

Pulse Analysis

Amphastar Pharmaceuticals entered 2026 with a pivotal regulatory win that could reshape its respiratory franchise. The FDA’s approval of ipratropium bromide HFA (AMP‑007) grants the company 180 days of generic exclusivity, positioning it as the first entrant in a market valued at over $100 million according to IQVIA data. This inhalation aerosol complements Amphastar’s existing portfolio of complex generics and adds a high‑margin, prescription‑only product that benefits from the firm’s U.S.-based manufacturing expertise. In a sector where speed to market and exclusivity windows drive profitability, the approval underscores Amphastar’s ability to leverage its R&D pipeline for meaningful revenue upside.

The fourth‑quarter results showed modest top‑line contraction, with full‑year net revenue of $719.9 million, a 2 percent decline driven primarily by legacy products such as glucagon and epinephrine. Nevertheless, the company delivered double‑digit growth in its flagship biologic Baqsimi, which generated $185.4 million, up 12 percent, and saw a 12 percent increase in Q4 sales. Primatene Mist contributed $108.7 million, rising 7 percent, while newer launches like iron sucrose added modest revenue. Gross margin held steady at 47 percent, but management warned of margin compression in 2026 as pricing pressure intensifies on high‑margin legacy drugs and input costs rise.

Looking ahead, Amphastar’s strategic focus centers on scaling production and expanding its pipeline. The Rancho Cucamonga facility upgrade will quadruple capacity, ensuring supply reliability for upcoming launches such as ipratropium bromide HFA and the company’s proprietary peptide programs in oncology, ophthalmology, and immunology. With over $300 million in cash and short‑term investments, the firm can fund capital expenditures, increased R&D spend, and a continued share‑repurchase program without diluting shareholders. The 2026 outlook targets mid‑ to high‑single‑digit revenue growth, albeit with lower gross margins, reflecting a trade‑off between aggressive market penetration and margin pressure—a balance that will be closely watched by investors.